Clinical Trial

A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabeled with a small amount of carbon-14 so it can be tracked in the body. This study will take place at one site in Nottingham, United Kingdom, and will enroll 2 groups of 8 healthy men aged 30-65 years.
Protocol Amendment History 2 changes
critical Trial completed 2026-06-23
notable Enrollment increased: 8 -> 16 participants 2026-06-23
Trial Details
NCT Number NCT07518459
Lead Sponsor AstraZeneca
Collaborators: Quotient Sciences
Conditions Healthy Participants
Enrollment 16 participants
Start Date 2026-02-11
Primary Completion 2026-05-26 (estimated)
Study Completion 2026-05-26 (estimated)
Updated on ClinicalTrials.gov 2026-06-22